Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy

The availability of tyrosine kinase inhibitors (TKI) during the past ten years has led to improved response and overall survival of patients suffering from metastatic clear cell renal cell carcinoma (ccRCC). However, most of these tumors will eventually progress due to resistance evolving under ther...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Dietz, Steffen, Sültmann, Holger, Du, YueJun, Reisinger, Eva, Riediger, Anja Lisa, Volckmar, Anna-Lena, Stenzinger, Albrecht, Schlesner, Matthias, Jäger, Dirk, Hohenfellner, Markus, Duensing, Stefan, Grüllich, Carsten, Pahernik, Sascha
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2017
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5650322/
https://ncbi.nlm.nih.gov/pubmed/29088767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18200
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk